The AtheroGene study


The AtheroGene study was conducted at the Department of Medicine II of the University Medical Center Mainz and the Federal Armed Forces Central Hospital Koblenz in Germany from 1996 to 2004 (31). The major goal of the AtheroGene study was to assess risk prediction across a wide range of coronary artery disease phenotypes with particular emphasis on the role of genetics. The major endpoint in this study was cardiovascular death and non-fatal myocardial infarction among other cardiovascular outcomes. Inclusion criteria for this study were prevalent coronary artery disease with angiographical diagnosis of a 30% or higher stenosis in a major coronary artery. Exclusion criteria were evidence of hemodynamically significant valvular heart disease, surgery or trauma within the previous month, known cardiomyopathy, malignancies, febrile conditions, chronic inflammatory diseases, renal failure (increased creatinine >2.1 mg/dL) or use of oral anticoagulant therapy within the previous four weeks. Patients presenting with solely elevated C-reactive protein concentrations were not excluded from the study cohort. Fasting blood was drawn prior to catheterization in the cath lab and processed immediately.

Return to the Cohorts


The BiomarCaRE project was co-funded by the European Community´s Seventh Framework Programme (FP7/2007-2013) under grant agreement N° HEALTH-F2-2011-278913. Copyright © 2011-2020 BiomarCaRE.eu - All Rights Reserved